Literature DB >> 20825389

Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.

Yan Chang1, Wenfang B Fang, Shen-Nan Lin, David E Moody.   

Abstract

In vitro metabolism of methadone was investigated in cytochrome P450 (CYP) supersomes and phenotyped human liver microsomes (HLMs) to reconcile past findings on CYP involvement in stereo-selective metabolism of methadone. Racaemic methadone was used for incubations; (R)- and (S)-methadone turnover and (R)- and (S)-EDDP formation were determined using chiral liquid chromatography-tandem mass spectrometry. CYP supersome activity for methadone use and EDDP formation ranked CYP2B6 > 3A4 > 2C19 > 2D6 > 2C18, 3A7 > 2C8, 2C9, 3A5. After abundance scaling, CYP3A4, 2B6 and 2C19 accounted for 63-74, 12-32 and 1. 4-14% of respective activity. CYP2B6, 2D6 and 2C18 demonstrated a preference for (S)-EDDP formation; CYP2C19, 3A7 and 2C8 for (R)-EDDP; 3A4 none. Correlation analysis with 15 HLMs supported the involvement of CYP2B6 and 3A. The significant correlation of S/R ratio with CYP2B6 activity confirmed its stereo-selectivity. CYP2C19 and 2D6 inhibitors and monoclonal antibody (mAb) did not inhibit EDDP formation in HLM. Chemical and mAb inhibition of CYP3A in high 3A activity HLM reduced EDDP formation by 60-85%; inhibition of CYP2B6 in 2B6 high-activity HLM reduced (S)-EDDP formation by 80% and (R)-EDDP formation by 55%. Inhibition changed methadone metabolism in a stereo-selective manner. When CYP3A was inhibited, 2B6 mediated (S)-EDDP formation predominated; S/R stereo-selectivity increased. When 2B6 was inhibited (S)-EDDP formation fell and stereo-selectivity decreased. The results confirmed the primary roles of CYPs 3A4 and 2B6 in methadone metabolism; CYP2C8 and 2C9 did not appear involved; 2C19 and 2D6 have minimal roles. CYP2B6 is the primary determinant of stereo-selective metabolism; stereo-selective inhibition might play a role in varied plasma concentrations of the two enantiomers.
© 2010 The Authors. Basic & Clinical Pharmacology & Toxicology © 2010 Nordic Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20825389      PMCID: PMC3005981          DOI: 10.1111/j.1742-7843.2010.00628.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  35 in total

1.  Cytochrome P450 2D6 genotype and methadone steady-state concentrations.

Authors:  C B Eap; F Broly; A Mino; R Hämmig; J J Déglon; C Uehlinger; D Meili; A F Chevalley; G Bertschy; D Zullino; M Kosel; M Preisig; P Baumann
Journal:  J Clin Psychopharmacol       Date:  2001-04       Impact factor: 3.153

2.  Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.

Authors:  K Venkatakrishnan; L L von Moltke; M H Court; J S Harmatz; C L Crespi; D J Greenblatt
Journal:  Drug Metab Dispos       Date:  2000-12       Impact factor: 3.922

Review 3.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Differential N-demethylation of l-alpha-acetylmethadol (LAAM) and norLAAM by cytochrome P450s 2B6, 2C18, and 3A4.

Authors:  J A Neff; D E Moody
Journal:  Biochem Biophys Res Commun       Date:  2001-06-15       Impact factor: 3.575

5.  Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.

Authors:  D J Foster; A A Somogyi; K R Dyer; J M White; F Bochner
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

6.  In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.

Authors:  J W Ko; Z Desta; N V Soukhova; T Tracy; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

7.  Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine.

Authors:  Tanja Richter; Thomas E Mürdter; Georg Heinkele; Jürgen Pleiss; Stephan Tatzel; Matthias Schwab; Michel Eichelbaum; Ulrich M Zanger
Journal:  J Pharmacol Exp Ther       Date:  2003-10-16       Impact factor: 4.030

8.  Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.

Authors:  Jun-Sheng Wang; C Lindsay DeVane
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

9.  Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.

Authors:  John G Gerber; Robert J Rhodes; Joseph Gal
Journal:  Chirality       Date:  2004-01       Impact factor: 2.437

10.  Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone.

Authors:  Francine Prost; Wolfgang Thormann
Journal:  Electrophoresis       Date:  2003-08       Impact factor: 3.535

View more
  38 in total

Review 1.  Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Gene D Morse
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

2.  Methadone-Associated Prolongation of the QTc Interval at Doses Used for Chronic Pain.

Authors:  James K McNamara; Nataliya Shinkazh; Fay Rim; Remy Sunga; Adrian Cristian
Journal:  P T       Date:  2011-02

3.  Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).

Authors:  Evan D Kharasch; Pamela Sheffels Bedynek; Christine Hoffer; Alysa Walker; Dale Whittington
Journal:  Anesthesiology       Date:  2012-02       Impact factor: 7.892

4.  A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study.

Authors:  John F Carlquist; David E Moody; Stacey Knight; Eric G Johnson; Wenfang B Fang; John A Huntinghouse; Jeffrey S Rollo; Lynn R Webster; Jeffrey L Anderson
Journal:  Mol Diagn Ther       Date:  2015-04       Impact factor: 4.074

Review 5.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

6.  Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine-naloxone in subjects receiving stable addiction management therapy.

Authors:  David Joseph; Michael J Schobelock; Robert R Riesenberg; Bradley D Vince; Lynn R Webster; Abidemi Adeniji; Mabrouk Elgadi; Fenglei Huang
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

7.  Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.

Authors:  Taha Ahmad; Samie Sabet; Donald A Primerano; Lauren L Richards-Waugh; Gary O Rankin
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

8.  Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.

Authors:  Sheng-Chang Wang; Ing-Kang Ho; Hsiao-Hui Tsou; Sheng-Wen Liu; Chin-Fu Hsiao; Chia-Hui Chen; Happy Kuy-Lok Tan; Linen Lin; Chi-Shin Wu; Lien-Wen Su; Chieh-Liang Huang; Yi-Hong Yang; Ming-Lun Liu; Keh-Ming Lin; Shu Chih Liu; Hsiao-Yu Wu; Hsiang-Wei Kuo; Andrew C H Chen; Yao-Sheng Chang; Yu-Li Liu
Journal:  OMICS       Date:  2013-09-09

9.  Perioperative pharmacokinetics of methadone in adolescents.

Authors:  Anshuman Sharma; Danielle Tallchief; Jane Blood; Thomas Kim; Amy London; Evan D Kharasch
Journal:  Anesthesiology       Date:  2011-12       Impact factor: 7.892

10.  Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and Metabolism.

Authors:  Evan D Kharasch; Karen J Regina; Jane Blood; Christina Friedel
Journal:  Anesthesiology       Date:  2015-11       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.